Contemporary use of bevacizumab in ovarian cancer

Expert Opinion on Biological Therapy

Volumn 13, Issue 2, 2013, Pages 283-294

  Miyake, Takahito M ^a   Sood, Anil K ^a   Coleman, Robert L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

adverse event; angiogenesis; bevacizumab; chemotherapy; clinical trial; ovarian cancer; primary ovarian cancer; recurrent ovarian cancer; review; treatment

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANEMIA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DRUG COST; DRUG EFFICACY; ENTERITIS; FEBRILE NEUTROPENIA; HUMAN; HYPERTENSION; INTESTINE PERFORATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECEPTOR BINDING; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872202099     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.745508     Document Type: Article

References (56)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
2. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-Analysis. J Clin Oncol 2002;120(5):1248-59 (Pubitemid 34177431)
3. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer 2009;19(Suppl 2):S63-7
4. Ziebarth AJ, Landen CN Jr., Alvarez RD. Molecular/genetic therapies in ovarian cancer: future opportunities and challenges. Clin Obstet Gynecol 2012;55(1):156-72
5. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011;17(11):1359-70
6. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40 (Pubitemid 43108832)
7. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;19473(7347):298-307
8. Angiogenesis inhibitors. National Cancer Institute at the National Institutes of health. Bethesda, MD. Available from: http://www.cancer.gov/ cancertopics/factsheet/Therapy/angiogenesis-inhibitors
9. Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol 2011;129(1):69-74
10. Biagi JJ, Oza AM, Chalchal HI, et al. A Phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011;22(2):335-40
11. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009;2027(33):5601-6
12. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010;119(1):32-7
13. Folkman J. Anti-Angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409-16
14. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996;32A(14):2386-93
15. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2(10):795-803 (Pubitemid 37328914)
16. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;1023(5):1011-27 (Pubitemid 46202320)
17. Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 2009;21(2):154-64
18. Herbert SP, Stainier DY. Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat Rev Mol Cell Biol 2011;12(9):551-64
19. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;8358(19):2039-49 (Pubitemid 351656458)
20. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2(10):727-39 (Pubitemid 37328908)
21. Huang S, Robinson JB, Deguzman A, et al. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 2000;160(19):5334-9
22. Bamias A, Pignata S, Pujade-Lauraine E. Angiogenesis: a promising therapeutic target for ovarian cancer. Crit Rev Oncol Hematol 2012; Epub ahead of print
23. Teoh D, Secord AA. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer 2012;22(3):348-59
24. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;165(3):671-80 (Pubitemid 40216420)
25. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 2004;38(7-8):1258-64 (Pubitemid 38802172)
26. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;7307(5706):58-62 (Pubitemid 40093472)
27. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;2025(33):5165-71 (Pubitemid 350237599)
28. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007;2025(33):5180-6 (Pubitemid 350232248)
29. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26(1):76-82
30. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;129(16):2259-64
31. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;127(7):1069-74
32. Monk BJ, Choi DC, Pugmire G, Burger RA. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol Oncol 2005;96(3):902-4
33. McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer 2011;15117(16):3731-40
34. Del Carmen MG, Micha J, Small L, et al. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol 2012;126(3):369-74
35. Belotti D, Vergani V, Drudis T, et al. The microtubule-Affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;Nov2(11):1843-9 (Pubitemid 26384151)
36. Hurt JD, Richardson DL, Seamon LG, et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009;115(3):396-400
37. O'Malley DM, Richardson DL, Rheaume PS, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol 2011;1121(2):269-72
38. Gonzalez-Martin A, Gladieff L, Tholander B, et al. Safety of front-line bevacizumab (BEV) combined with weekly paclitaxel (wPAC) and q3w carboplatin (C) for ovarian cancer (OC): results from OCTAVIA. J Clin Oncol 2012;30(Suppl):abstract 5017
39. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;29365(26):2473-83
40. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;29365(26):2484-96
41. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;1030(17):2039-44 .. These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer.
42. Aghajanian C, Nycum LR, Goff B, et al. Gynecological cancers/967OUpdated overall survival analysis in OCEANS, a randomized phase 3 trial of gemcitabine (G) + carboplatin (C) and bevacizumab (BV) or placebo (PL) followed by BV or PL in platinum-sensitive recurrent epithelial ovarian (ROC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Ann Oncol 2012;23(Suppl 9):ix319
43. Pujade-Lauraine E, Hilpert F, Weber B, et al. AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)- resistant recurrent ovarian cancer (OC). J Clin Oncol 2012;30(Suppl): abstract LBA5002 .These results suggest that the risk of GIP seems to be in line with prescribing information when the number of prior chemotherapy regimens is restricted to two or fewer.
44. Hagemann AR, Zighelboim I, Novetsky AP, et al. Phase II trial of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2012;30(Suppl): abstract 5013
45. Tillmanns TD, Lowe MP, Walker MS, et al. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 2012; [Epub ahead of print]
46. Miles D, Haas SD, Dirix L, et al. Plasma biomarker analysis in the AVADO phase III randomized study of first-line bevacizumab + docetaxel in patients with human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer. Cancer Res 2010;70:24 Suppl 2:Abstract P2-16-04
47. Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012;1030(17):2119-27
48. Lambrechts D, Claes B, Delmar P, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol 2012;13(7):724-33
49. Birrer MJ, Lankes H, Burger RA, et al. Biomarkers/198 Biomarker results from GOG-0218, a phase III trial of front-line bevacizumab plus chemotherapy for ovarian cancer. Ann Oncol 2012;2012;23(Suppl 9):ix81-2 This is the first biomarker analysis of bevacizumab trial in ovarian cancer patients.
50. Coleman RL, Duska LR, Ramirez PT, et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011;12(12):1109-17
51. Prescribing information of Avastin, Genentech, Inc. San Francisco, CA. 2012.Available from: http://www.gene.com/gene/products/information/pdf/avastin- prescribing.pdf
52. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-Analysis. JAMA 2011;2305(5):487-94
53. Aghajanian C, Blank SV, Goff BA, et al. An updated safety analysis of OCEANS, a randomized, double-blind, phase III trial of gemcitabine (G) and carboplatin (C) with bevacizumab (BV) or placebo (PL) followed by BV or PL to disease progression (PD) in patients with platinum-sensitive (Plat-S) recurrent ovarian cancer. J Clin Oncol 2012;30(Suppl):abstrACT 5054
54. Cohn DE, Kim KH, Resnick KE, et al. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011;129(10):1247-51
55. The Cancer Genome Atlas. National Cancer Institute at the National Institutes of Health. Bethesda, MD. Available from: http://cancergenome.nih.gov/
56. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009;2101(23):1642-9